Table 1.
Demographic Summary of 168 Primary Glioblastoma Patients
| Bev N = 49 |
Bev/CCNU N = 53 |
CCNU 09-15 N = 36 |
CCNU 01-04 N = 30 |
P Value | |
|---|---|---|---|---|---|
| Alive/Censored | 6 (12%) | 10 (19%) | 13 (36%) | 2 (7%) | 0.0093a |
| Death | 43 (88%) | 43 (81%) | 23 (64%) | 28 (93%) | |
| Age at Diagnosis | |||||
| Median | 63.44 | 56.87 | 57.4 | 53.36 | 0.0043b |
| Range | 39.95-80.4 | 40.27-75.54 | 25.99-83.4 | 20.78-78.18 | |
| Gender | |||||
| Female | 25 (51%) | 17 (32%) | 17 (47%) | 12 (40%) | 0.2387a |
| Male | 24 (49%) | 36 (68%) | 19 (53%) | 18 (60%) | |
| KPS at First Recurrent Treatment | |||||
| ≥70 | 39 (80%) | 50 (94%) | 32 (89%) | 24 (80%) | 0.1127a |
| <70 | 10 (20%) | 3 (6%) | 4 (11%) | 6 (20%) | |
| Tumor 2D (mm2) | |||||
| Nonmissing N | 47 | 51 | 36 | 24 | <0.0001b |
| Median | 1196.06 | 1545.05 | 504.88 | 743.24 | |
| Range | 0-6315.35 | 0-4219.72 | 0-2818.09 | 0-4285.3 | |
| Tumor 3D (mm3) | |||||
| Nonmissing N | 46 | 50 | 36 | 22 | 0.0002b |
| Median | 12372.87 | 20991.92 | 3350.91 | 14859.23 | |
| Range | 944.48-86992.79 | 0-115250.95 | 0-44140.48 | 0-170873.55 | |
| Crossover to Bev | |||||
| No | NA | NA | 11 (31%) | 28 (93%) | <0.0001a |
| Yes | NA | NA | 25 (69%) | 2 (7%) | |
Abbreviations: Bev, bevacizumab; CCNU, lomustine; KPS, Karnofsky Performance Status; NA, not available.
achi-square test.
bAnalysis of variance test.